CDK 4/6 inhibitors

Ibrance (palbociclib)

The drug was reviewed and approved under the Food and Drug Administration’s (FDA) accelerated Priority Review and Breakthrough Therapy designation programs on February 3, 2015 as a treatment (in combination with letrozole) for patients with estrogen receptor positive advanced breast cancer...Wikipedia

 

 

Manufacturer's Website: Ibrance                                                                                                                                               Average retail cost: $11,200/vial

Kisqali (ribociclib)

Ribociclib (trade name Kisqali) is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. It is also being studied as a treatment for other drug-resistant cancers...Wikipedia

 

 

Manufacturer's Website: Kisqali                                                                                                                                               Average retail cost: $11,200/vial

Verzenio (abemaciclib)

Abemaciclib (trade name Verzenio) is a drug for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6. It was designated as a breakthrough therapy by the U.S. Food and Drug Administration in October 2015. On 28 September 2017, it was approved for use in the United States by the Food and Drug Administration for the treatment of certain breast cancers....Wikipedia

 

 

Manufacturer's Website: Verzenio                                                                                                                                               Average retail cost: $11,400/vial

Copyright 2006-2020 Automated Clinical Guidelines, LLC. All rights reserved.

™